Alexander Shulgin Research Institute (ASRI) Company Profile

Background

The Alexander Shulgin Research Institute (ASRI) is a pioneering organization dedicated to the discovery and development of novel psychedelic and entactogenic compounds for therapeutic applications. Established in 2021 by Ann Shulgin, Dr. Paul Daley, and Dr. Nicholas Cozzi, ASRI continues the legacy of Dr. Alexander "Sasha" Shulgin, renowned for his extensive work in synthesizing and characterizing psychoactive substances. The institute's mission is to advance psychedelic science, unlock new insights into the human psyche, and transform mental health paradigms.

Key Strategic Focus

ASRI's strategic objectives encompass:

Chemical Synthesis and Pharmacological Evaluation: Designing, synthesizing, and characterizing novel compounds to identify substances with potential psychedelic activity.

Natural Product Isolation: Isolating and identifying naturally occurring compounds from plants and other sources to discover new psychoactive substances.

Preclinical and Clinical Research: Conducting in vitro and in vivo studies to assess the pharmacological profiles and therapeutic potential of both newly synthesized and existing compounds.

Intellectual Property Development: Securing patents for new compounds and their therapeutic uses to protect intellectual property and support financial sustainability.

Collaborative Partnerships: Engaging with academic institutions, medical communities, pharmaceutical companies, and government agencies to facilitate knowledge exchange and collaborative research.

The institute targets conditions such as neurological, neurodevelopmental, neuropsychiatric disorders, pain syndromes, inflammation, and overall wellness enhancement.

Financials and Funding

In December 2021, ASRI completed a seed financing round, raising $7.2 million. The round was led by Noetic Fund, which committed $6.95 million. The funding is intended to support the establishment of the Shulgin Research Laboratory, advance the synthesis and evaluation of novel compounds, and facilitate preclinical and clinical research initiatives.

Pipeline Development

ASRI's pipeline includes several promising compounds:

ASR-3001 (5-MeO-iPALT): A second-generation, fast-acting tryptamine designed to produce an internal psychedelic state without sensory or visual disturbances.

ASR-2001 (2CB-5PrO): A phenethylamine-based non-hallucinogenic serotonin 5-HT₂A receptor agonist, with potential applications in treating attention-deficit hyperactivity disorder (ADHD) and self-improvement in healthy individuals.

XOB (ASR-6001): A bifunctional compound acting as a serotonin 5-HT₂A receptor antagonist and voltage-gated sodium channel blocker, showing promise for bipolar disorder treatment.

These compounds are in various stages of preclinical development, with ongoing studies to assess their safety, efficacy, and therapeutic potential.

Technological Platform and Innovation

ASRI leverages several proprietary technologies and methodologies:

Shulgin Vault: A repository containing over 500 compounds synthesized by Dr. Alexander Shulgin and ASRI scientists, offering a vast library of novel variations of phenylalkylamines, tryptamines, lysergamides, isoquinolines, cathinones, and more.

Chemical Synthesis: Advanced techniques for the design and synthesis of novel psychedelic compounds.

Pharmacological Profiling: In vitro and in vivo assays to evaluate receptor binding, functional activity, and behavioral effects of compounds.

Intellectual Property: ASRI has filed and been granted several patents covering various entactogenic and psychedelic compounds, including deuterated and fluorinated empathogens, as well as asymmetric allyl tryptamines.

Leadership Team

Dr. Nicholas V. Cozzi: Co-Founder and President. Dr. Cozzi is a pharmacologist and neuroscientist with extensive experience in the study of psychoactive substances.

Dr. Paul F. Daley: Co-Founder and Chief Science Officer. Dr. Daley is a chemist specializing in the synthesis of novel compounds and has been instrumental in continuing Dr. Shulgin's work.

Dr. Andrew Bartynski: Chief Operations Officer and Vice President of Strategy and Operations. Dr. Bartynski brings expertise in strategic planning and operational management within the pharmaceutical industry.

Leadership Changes

As of March 2025, Dr. Paul Daley succeeded Dr. Nicholas V. Cozzi as President of ASRI. Dr. Cozzi continues to serve as Director of Pharmacology, focusing on the institute's research initiatives.

Competitor Profile

Market Insights and Dynamics

The psychedelic medicine industry is experiencing rapid growth, driven by increasing recognition of the therapeutic potential of psychedelics in treating mental health disorders. The market is characterized by a surge in research and development activities, regulatory advancements, and a growing number of clinical trials.

Competitor Analysis

MiHKAL GmbH: A Swiss pharmaceutical company developing psychedelics and entactogens as potential medicines. MiHKAL has filed patents on prodrugs of psychedelics and entered a non-exclusive partnership with Compass Pathways to develop novel compounds.

CaaMTech, Inc.: Collaborated with ASRI to study novel compounds from the Shulgin Vault, focusing on structural and chemical analyses to identify therapeutic potential.

Negev Labs LLC: A biotechnology company focused on developing neuroplastogens, a novel class of psychedelic-based therapeutics that promote neural remodeling without hallucinogenic effects. Negev Labs has entered into a licensing agreement with ASRI to access its extensive library of drug candidates.

Strategic Collaborations and Partnerships

Negev Labs LLC: In December 2024, ASRI entered into a licensing agreement with Negev Labs, providing access to its extensive library of drug candidates for the development of neuroplastogens.

CaaMTech, Inc.: In July 2022, ASRI collaborated with CaaMTech to conduct structural and chemical analyses of previously unreported compounds from the Shulgin Vault, aiming to identify substances with therapeutic potential.

Operational Insights

ASRI's strategic considerations include:

Market Positioning: Leveraging its unique repository of compounds and expertise to establish a leading position in the psychedelic medicine industry.

Competitive Advantages: Possession of the Shulgin Vault, a comprehensive collection of psychoactive compounds, and a leadership team with deep expertise in psychedelic research.